Home » Covid: One dose AstraZeneca or Pfizer reduces risk by 2 thirds, study

Covid: One dose AstraZeneca or Pfizer reduces risk by 2 thirds, study

by admin

Milan, 23 April (beraking latest news Health) – One dose of Covid vaccine from Oxford / AstraZeneca or Pfizer / BioNTech reduces the risk of infection by nearly two-thirds, and protects older and more vulnerable people as well as younger, healthier ones. This is what emerges from a study by the University of Oxford and the British Office for National Statistics, conducted by analyzing the results of Covid tests on over 350 thousand people in the United Kingdom between December and April.

This is the “first study – reads the ‘Guardian’ – to evaluate the impact” of the first dose “on the new” Sars-CoV-2 coronavirus infections “and the immune responses in a large group of adults in the general population. By reducing infection rates, vaccines not only prevent hospitalizations and deaths, but help to break the chains of transmission and thus reduce the risk of a harmful resurgence of the disease following the reopening “in progress in the UK.”

The researchers noted that, 21 days after the first administration, new Covid infections decreased by 65%. Vaccines proved more effective against symptomatic infections (-72%) than asymptomatic ones (-57%). A second dose of Pfizer vaccine, for which the effect of the booster can be estimated having been approved and launched first compared to that of AstraZeenca, further enhanced protection, with a 90% reduction in symptomatic infections and a 70% reduction. of the asymptomatic ones. The results, released today in a preprint version, according to the authors support the UK’s decision to prioritize the administration of a first dose of the vaccine to older and more vulnerable people, delaying boosters.

See also  Xbox’s countdown promotion starts with massive discounts--Gamereactor

The results are considered “particularly important because they demonstrate the protective effect of vaccines in the real world“, also “against the Kent variant (the so-called English variant, Ed)” of the coronavirus, “highly infectious” and according to some data “more lethal,” that was not circulating during clinical trials “on investigational vaccines.

Another work by the same group of scientists, reported in a second preprint, analyzed the antibody responses to the two vaccines. Injection-induced antibodies increased faster, reaching a higher level, after the first dose of Pfizer vaccine, but then dropped to a similar level to that seen after the AstraZeneca vaccine, especially in older people.

Although the immune responses were different, David Eyre of the Big Data Institute in Oxford points out that a strong antibody response was achieved in 95% of people. In young people, a dose of the vaccine induces an increase in antibodies similar to that observed after Covid infection, while in the elderly this occurs after two doses. “Our findings underscore the importance of the recall to ensure greater protection,” recommends Eyre.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy